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Introduction
Although human fibrotic lung disorders cause substantial morbidity and mortality, we know relatively little 
about their pathogenesis and have few highly effective treatments for them (1). In addition, although genetic 
factors are believed to play important roles in the regulation and progression of  human fibrotic disorders, 
the factors that account for the variations in the development and progression of  pulmonary fibrosis have 
not been defined (2, 3). Idiopathic pulmonary fibrosis (IPF) is a prototypical fibrotic lung disorder that is 
characterized by epithelial damage, fibroproliferative matrix deposition and parenchymal remodeling (4–6). 
TGF-β1, a multifunctional cytokine that plays pivotal roles in diverse biologic processes, is believed to play an 
important role in the pathogenesis of  this disorder. This is based on studies that demonstrate that (i) TGF-β1 
is an essential mediator of  the pathologic scarring in a variety of  fibrotic disorders (7–12); (ii) a high level 
of  biologically active TGFβ-1 is expressed in IPF tissue (13–15); (iii) TGFβ-1 is a critical mediator of  the 
bleomycin-induced pulmonary fibrosis in rodent modeling systems (10, 11); and (iv) TGF-β1 overexpression 
causes progressive pulmonary fibrosis in vivo (16, 17) and in vitro (15). In accordance with these observations, 
the juxtaposition of  tissue injury, fibrosis, and exaggerated TGF-β1 expression are well documented in IPF 
(18–21). However, the pathways that mediate and the factors that regulate the fibrogenic effects of  TGF-β1 
are poorly understood. Moreover, the rate of  progression, severity, and response to therapy observed in IPF 
patients are extremely variable, and the factors that contribute to this variability have not been defined (22).
In addition to its roles in the generation of  fibrotic tissue and cellular responses, recent studies have high-
lighted a wide variety of  other TGF-β1–induced effector responses and the fact that these responses can 
appear to contradict one another (7, 23–25). In keeping with its importance in fibrosis, TGF-β1 is essential 
for wound healing and stimulates matrix molecule deposition and angiogenesis in some settings. In contrast, 
in other settings TGF-β1 can also induce tissue injury and cellular apoptosis, decrease epithelialization, and 
inhibit wound healing (23, 25–28). Similarly, TGF-β1 has important antiinflammatory (29, 30) and proin-
The pathogenetic mechanisms underlying the pathologic fibrosis in diseases such as idiopathic 
pulmonary fibrosis (IPF) are poorly understood. To identify genetic factors affecting susceptibility 
to IPF, we analyzed a murine genetic model of IPF in which a profibrotic cytokine (TGF-β1) was 
expressed in the lungs of 10 different inbred mouse strains. Surprisingly, the extent of TGF-β1–
induced lung fibrosis was highly strain dependent. Haplotype-based computational genetic 
analysis and gene expression profiling of lung tissue obtained from fibrosis-susceptible and 
-resistant strains identified laminin α1 (Lama1) as a genetic modifier for susceptibility to IPF. 
Subsequent studies demonstrated that Lama1 plays an important role in multiple processes 
that affect the pulmonary response to lung injury and susceptibility to fibrosis, which include: 
macrophage activation, fibroblast proliferation, myofibroblast transformation, and the production 
of extracellular matrix. Also, Lama1 mRNA expression was significantly increased in lung tissue 
obtained from IPF patients. These studies identify Lama1 as the genetic modifier of TGF-β1 effector 
responses that significantly affects the development of pulmonary fibrosis.
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flammatory effects (30, 31) in different settings. In accordance with this complexity and in contrast to its roles 
in fibrosis, TGF-β1 has also been implicated in the pathogenesis of  diseases characterized by tissue destruc-
tion, such as the emphysema in chronic obstructive lung disease (COPD) (32, 33). However, the mechanisms 
that contribute to these complex and context-dependent effects of  TGF-β1 have not been defined.
To begin to characterize effector responses of  TGF-β1, we generated transgenic (Tg) mice in which 
bioactive TGF-β1 was inducibly targeted to the murine lung. These mice were initially on a C57BL/6J 
(C57) murine genetic background. As expected, the TGF-β1 transgene induced a prominent pulmonary 
fibrotic response in these C57 background animals (34). In contrast, when the mice were bred for more 
than 10 generations onto a BALB/c background, the same level of  transgene expression induced a phe-
notype in which fibrosis was markedly diminished and tissue destruction and emphysema dominated the 
tissue response. These differences demonstrated that genetic modifiers play a critical role in determining the 
biologic responses that are induced by TGF-β1. To further define these genetic modifier(s), the TGF-β1 Tg 
mice were bred for more than 10 generations onto 10 different inbred murine strains. and their phenotypes 
were assessed and compared. These studies demonstrated that the extent of  pulmonary fibrosis was highly 
strain dependent. Haplotype-based computational genetic mapping (HBCGM) and mRNA profiling of  
the lungs obtained from fibrosis-prone and -resistant mice identified laminin α1 (Lama1) as a genetic mod-
ifier of  pulmonary fibrosis. Subsequent in vivo and in vitro studies highlighted strain-specific differences 
in Lama1 expression in key cell types and the critical role(s) of  Lama1 in determining the magnitude of  
TGF-β1–induced pulmonary repair and or fibrotic responses. The disease relevance of  these murine find-
ings was also confirmed in studies that demonstrated that the levels of  Lama1 expression are increased in 
lung tissues from patients with IPF versus controls.
Results
The extent of  pulmonary fibrosis is strain dependent. To define the mechanisms that underlie the heterogeneity 
of  TGF-β1 effector responses, we generated Tg mice in which bioactive TGF-β1 was inducibly expressed 
in the lungs of  C57 mice (34). Then, this transgene was bred for more than 10 generations onto 9 other 
strains (BALB/cJ, C3H/HeJ, CBA/J, 129Si/J, FVB/J, NZW/J, DBA/J, AKR/J, and A/J). As previously 
described, bioactive TGF-β1 induced epithelial apoptosis and subsequent pulmonary fibrosis in C57 mice 
(Figure 1A) (34). The fibrogenic response in C57 mice was much more prominent than in the lungs of  Tg 
BALB/c mice (Figure 1A). When the pulmonary phenotypes in all 10 strains were compared, it became 
clear that there was an extensive amount of  fibrosis in certain strains (A/J, AKR, DBA, and C57), while 
others (C3H, BALB/c, CBA, and 129Si) had markedly reduced levels of  collagen accumulation (Figure 1B 
and Table 1). Across the 10 strains, the collagen concentration in the lungs of  TGF-β1 Tg mice varied from 
15 μg/ml (C3H) to 66 μg/ml (A/J). The observed inter-strain difference was strong and very significant (P 
= 4 × 10–27), suggesting that the observed variations were indeed due to genetic differences. These differenc-
es represented intrinsic properties of  the genetic backgrounds of  the strains. They could not be explained 
by differences in the level of  Tg TGF-β1 expression, because comparable levels of  TGF-β1 were present in 
bronchoalveolar lavage (BAL) fluid obtained from the 10 inbred strains after doxycycline induction (Sup-
plemental Figure 1). These results demonstrate that the pulmonary responses to TGF-β1 depend upon 
genetic modifiers present in the genetic background of  the different strains.
Identification of  Lama1 as a genetic modifier of  TGF-β1–stimulated pulmonary fibrosis. To identify genetic mod-
ifiers of  TGF-β1 responses, HBCGM was used to analyze the fibrogenic responses (collagen levels) in the 
10 inbred strains as previously described (35). This analysis indicated that 560 genes had allelic patterns that 
correlated with the extent of  collagen accumulation (using a P value cutoff  of  0.01; Supplemental Table 1). 
In order to prioritize this extensive candidate gene list, we compared the lung gene expression profiles of  
fibrosis-prone (C57, AKR/J, A/J) and fibrosis-resistant (C3H/J, 129 Si/J, and BALB/c) TGF-β1 Tg mice. 
For each strain, we determined the expression fold change of  each gene transcript in Tg mice compared with 
controls. We identified 127 genes with at least a 2-fold difference on average in the fibrosis-prone strains but 
less than a 2-fold change in fibrosis-resistant strains (Supplemental Table 2). Finally, by intersecting the lists of  
genes identified by HBCGM and by gene expression profiling, 3 candidate genetic modifiers were identified: 
Lama1, Wisp1, and Hba-a1 (Figure 1C). Of these, Lama1 was selected for analysis based on its relatively high 
genetic effect (O.83) and consistent responsiveness to TGF-β1 stimulation in vivo and in vitro (Figure 1D 
and see below). A schematic illustration of  the overall selection process and expression levels of  Lama1 in 
fibrosis-prone and -resistant strains of  mice is shown in Supplemental Figure 2. We identified 851 SNPs that 
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Figure 1. Identification of Lama1 as a genetic modifier of TGF-β–stimulated pulmonary fibrosis. Lungs from 6- to 8-week-old WT and TGF-β1–Tg mice on the 
noted genetic backgrounds were evaluated after the mice were given doxycycline in drinking water for 14 days of to induce Tg. (A) Mallory trichrome evaluation 
(left panel) and total collagen content measured by Sircol collagen assay (right panel) of lungs from WT and TGF-β1 Tg mice on C57BL/6J (C57) and BALB/cJ (BAL-
B/c) backgrounds. Scale bars: 25 μm. (B) Levels of collagen in lungs from WT and Tg mice on 10 different background strains were measured by Sircol evaluations 
(n = 7 for each). (C) Illustration of haplotype blocks of Lama1, Wisp1, and Hba-a1. The haplotype of each gene is represented by a colored block, and is presented 
in the same order as the phenotypic data shown in B. (D) Kinetic evaluation (using qRT-PCR) of the levels of mRNA encoding Lama1 in lungs from WT and TGF-β1 
Tg mice on C57 and BALB/c backgrounds at various time points after transgene induction with doxycycline (DOX). (E) Expression of Lama1 mRNA in the lungs of 
bleomycin-challenged C57 and BALB/c mice. The histology shown in A is representative of at least 5 mice per each group. The values in A, B, D, and E represent 
mean ± SEM of a minimum number of 5 mice in each group. Post-Bleo, days after bleomycin challenge. *P < 0.05. **P < 0.01. #P < 0.001.
4insight.jci.org   https://doi.org/10.1172/jci.insight.99574
R E S E A R C H  A R T I C L E
were variable among these 10 strains, among which 
15 coding SNPs induced amino acid changes. Addi-
tional evidence supporting a critical role for Lama1 
was found when the baseline levels and levels of  
TGF-β1–stimulated expression of  pulmonary Lama1 
were examined. These studies demonstrated that 
both were significantly higher in C57 Tg mice than in 
BALB/c mice (Figure 1D). Similar time-dependent 
increases in the expression of  Lama1 were noted in 
the lungs of  bleomycin-challenged C57 mice, another 
animal model of  pulmonary fibrosis, and the levels 
of  Lama1 expression in C57 mice were significantly 
higher than in BALB/c mice (Figure 1E).
Strain-dependent localization of  Lama1 expression in 
the lungs of  TGF-β1 Tg mice. Studies were next under-
taken to localize the expression of  Lama1 in lungs 
from C57 and BALB/c TGF-β1 Tg mice. Low levels 
of  Lama1 expression were noted in the regions near 
the basement membranes as well as interstitial areas of  lungs from both strains of  mice (Figure 2A). Inter-
estingly, Lama1 expression was prominently induced in macrophages in lungs from C57 TGF-β1 Tg mice 
but not in lungs from BALB/c TGF-β1 Tg mice. This strain-specific macrophage expression was further 
confirmed by double-label IHC staining using CD68 macrophage-specific and Lama1 antibodies (Figure 2B). 
The differential induction of  Lama1 by TGF-β1 was also confirmed in vitro using alveolar macrophages iso-
lated from C57 and to BALB/c animals (Supplemental Figure 3). Similarly, TGF-β1 significantly induced the 
expression of  Lama1 in fibroblasts from C57 mice but did not have comparable effects in cells from BALB/c 
animals (Figure 2C). Interestingly, the TGF-β–stimulated Smad2 activation was markedly decreased with 
Lama1 siRNA silencing in the fibroblasts from C57 but not BALB/c mice (Figure 2D). Collectively these 
studies demonstrate that TGF-β1 stimulates Lama1 expression in a strain-specific and cell-specific manner, 
with TGF-β1 inducing a high level of  Lama1 expression in macrophages and fibroblasts of  fibrogenic C57 
mice, and with significantly lower levels of  induction in fibrosis-resistant BALB/c mice.
Lama1 plays a critical role in TGF-β1–stimulated pulmonary fibrosis. To investigate the role(s) of  Lama1 in 
TGF-β1–induced pulmonary fibrosis, Lama1-specific siRNA experiments were performed. In these experi-
ments, 6- to 8-week-old C57 WT and TGF-β1 Tg mice were treated with Lama1-specific (3 nmol/mouse/d) 
or control (scrambled) siRNAs every other day via nasal aspiration, and the extent of  collagen accumulation 
in the lungs was characterized using Mallory trichrome staining and Sircol assays 2 weeks later. In these 
experiments, Lama1-specific siRNA decreased TGF-β1–stimulated pulmonary Lama1 mRNA expression 
by more than approximately 90% to levels comparable to those in WT mice (Supplemental Figure 4). This 
Lama1 siRNA silencing significantly decreased the collagen accumulation in lungs of  TGF-β1 Tg mice com-
pared with those receiving control siRNA (Figure 3A). Similarly, levels of  expression of  extracellular matrix 
proteins (type I and III collagens, fibronectin) were markedly decreased in lungs from Lama1-specific siRNA–
treated TGF-β1 Tg mice (Figure 3B). In addition, the accumulation of  α–smooth muscle actin+ (α-SMA+)/
myosin– myofibroblasts surrounding airways in the lungs of  C57 TGF-β1 Tg mice was also markedly reduced 
in the lungs of  mice treated with Lama1-specific siRNA compared with controls treated with scrambled 
control siRNA (Figure 3C). We also noted increased α-SMA staining in the interstitial areas of  TGF-β Tg 
mice, and Lama siRNA silencing significantly reduced the α-SMA–positive region compared with scrambled 
siRNA–treated mice (Figure 3D). These studies demonstrated that Lama1 plays a critical role in TGF-β1–
stimulated pulmonary fibrosis, collagen accumulation, and in myofibroblast accumulation.
Role of  Lama1 in alternative and fibrotic (reparative) macrophage activation. Since Lama1 is highly induced 
in pulmonary macrophages in C57 TGF-β1 Tg mice, we characterized the role(s) of  Lama1 in macrophage 
activation. Lama1 induction in alveolar macrophages was significant at later fibrotic phases in the lung 
of  TGF-β1 Tg mice (Supplemental Figure 5), supporting an important role of  macrophage Lama1 in the 
fibrotic phase of  pulmonary fibrosis. The responses of  alveolar macrophages obtained from C57 mice to 
ligands that are known to induce specific macrophage activation paradigms were evaluated in cells that had 
been treated with Lama1-specific siRNA or scrambled controls in vitro. As expected, in vitro treatment 
Table 1. Soluble collagen levels in the lungs from WT and TGF-β Tg mice on 
different background strains measured by Sircol collagen assay
Strain WTA TGF-β TgA
C3H/HeJ 3.92 ± 0.32 14.73 ± 1.11
BALB/cJ 4.20 ± 0.15 20.70 ± 1.62
CBA/J 4.01 ± 0.56 20.57 ± 1.26
129Si/SvJ 3.97 ± 0.50 26.25 ± 1.47
FVB/NJ 4.10 ± 0.39 29.83 ± 2.29
NZW/LacJ 4.06 ± 0.53 43.18 ± 2.70
C57/BL6J 4.13 ± 0.53 48.57 ± 3.19
DBA/2J 4.01 ± 0.44 49.08 ± 1.58
AKR/J 3.97 ± 0.17 59.95 ± 2.84
A/J 4.09 ± 0.47 65.60 ± 2.34
AValues are mean ± SEM of collagen concentration of right lungs (μg/ml) from 7 mice/strain 
measured by Sircol collagen assay.
5insight.jci.org   https://doi.org/10.1172/jci.insight.99574
R E S E A R C H  A R T I C L E
of  cells that had received the scrambled control with recombinant IL-4 (rIL-4) stimulated the expression 
of  known markers of  alternative (M2) activation, including CD206, YM-1, Arg-2, Cxcr1, and Ccl1 (Fig-
ure 4A). In contrast, these rIL-4–induced responses were significantly reduced in macrophages in which 
Lama1 had been effectively silenced (Figure 4A). TGF-β1 is also known to induce alternative and fibrotic 
(reparative) macrophage activation (36, 37). This includes the stimulation of  a multiple markers including 
CD163, CD204, Fizz1, collagen type I (Col1α1), and collagen type III (Col3α1). These rTGF-β1–stimu-
Figure 2. Strain- and cell-dependent Lama1 expression in lungs from TGF-β Tg mice. Lungs from doxycycline-treated TGF-β1 Tg mice on the noted genetic 
backgrounds were evaluated. (A) Representative Lama1 IHC evaluation comparing C57 and BALB/c TGF-β Tg mice. White arrow indicates Lama1 positive 
macrophages while blue arrow indicates Lama1 stained area of basement membrane (lightly stained compared to macrophages) (B) Double IHC using 
anti-Lama1 (green) and anti-CD68 (red) antibodies. Arrows indicate cells stained with, Lama1, CD68 (macrophage specific marker), or both. Scale bars in A 
and B: 25 μm. (C) Fibroblasts were established from lungs of C57 and BALB/c mice and treated with TGF-β1 for 2 or 24 hours. The levels of Lama1 mRNA 
were evaluated by qRT-PCR. (D) Western blot evaluation on Smad2 activation in fibroblasts from C57 and BALB/c mice with and without TGF-β stimula-
tion. A, B, and D represent evaluations in a minimum of 3 mice. Values in C represent mean ± SEM of evaluations in a minimum of 5 mice in each group. 
**P < 0.01, ***P < 0.001 compared with controls with no TGF-β treatment.
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Figure 3. Lama1 plays an essential role in TGF-β–stimulated pulmonary 
fibrosis. Lungs from 8-week-old WT and TGF-β1 Tg mice were evaluated after 
2 weeks of Tg induction by doxycycline in drinking water. (A) Histologic evalua-
tion with Mallory trichrome staining (left) and evaluation of lung collagen con-
tent with Sircol assays (right) comparing WT and Tg lungs from mice treated 
with control scrambled siRNA and Lama1 siRNA. (B) qRT-PCR evaluation of the 
levels of mRNA encoding extracellular matrix proteins (collagen type1 alpha1 
[Col1a1], Col3a1, and fibronectin [FiN]) in lungs from WT and Tg mice treated 
with control scrambled siRNA or Lama1 siRNA. (C) Representative fluorescence 
double-label IHC evaluation of α–smooth muscle actin (α-SMA, red), CC10 
(green), and nuclei (DAPI, blue) in lungs from WT and TGF-β1 Tg mice treated 
with scrambled control siRNA or Lama1 siRNA (left panels). Double-label IHC 
evaluation of α-SMA (green), myosin (red), and nuclei (DAPI, blue) in lungs 
from TGF-β1 Tg mice treated with scrambled siRNA control or Lama1 siRNA 
(right panels). (D) α-SMA IHC staining of the lungs of TGF-β1 Tg mice with 
scrambled siRNA or Lama1 siRNA silencing. Arrows indicate positively stained 
cells in the interstitial area in the lungs of C57 TGF-β1 Tg mice. A (left) and C are 
representative of evaluations in a minimum of 3 mice. The values in A and B 
represent mean ± SEM of evaluations in a minimum of 5 mice each group. *P < 
0.05, **P < 0.01. Scale bars: 100 μm (A); 25 μm (C and D).
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lated responses were readily apparent in cells treated with the scrambled control and significantly amelio-
rated in macrophages in which Lama1 was silenced (Figure 4B). Importantly, Lama1 silencing did not 
alter the ability of  recombinant IFN-γ to induce expression levels of  M1 macrophage activation (iNOS 
[NOS2] and IP-10) (Figure 4C). The in vitro Lama1 silencing was highly effective, as illustrated in Figure 
4D. Alveolar macrophages isolated from the TGF-β Tg mice receiving Lama1 siRNA demonstrated similar 
decreases in fibrotic macrophage activation (Supplemental Figure 6), supporting a specific role for Lama1 
in the macrophage activation process. To further evaluate the in vivo relevance of  these findings, we also 
studied macrophages isolated from C57BL/6J-Lama1nmf223 mice with a functional missense mutation at the 
N-terminal end of  Lama1 (38). In accordance with our findings, macrophages from mice with a function-
al missense mutation of  Lama1 also manifested blunted alternative and fibrotic macrophage activation 
and unchanged classical macrophage activation responses when stimulated with IL-4, TGF-β1, or IFN-γ, 
respectively (Supplemental Figure 7). These Lama1 mutant mice also demonstrated reduced lung fibrosis 
with bleomycin challenge compared with normal controls, further supporting an in vivo functional role 
of  Lama1 in pulmonary fibrosis (Supplemental Figure 8). These studies demonstrate that Lama1 plays a 
critical role in alternative and fibrotic macrophage activation.
Role of  Lama1 in fibroblast proliferation, myofibroblast transformation, and TGF-β1 signaling. Fibroblasts are one 
of the major effector cell types responsible for tissue fibrotic responses. Because TGF-β1 is a potent stimulator 
of fibroblast Lama1 expression in C57 but not in BALB/c mice (Figure 2C), studies were undertaken to define 
the roles of Lama1 in TGF-β1–induced fibroblast responses. In these experiments, we compared the responses 
of TGF-β1–stimulated normal human lung fibroblasts (NHLFs) when treated with Lama1 siRNA or scrambled 
controls. The Lama1 silencing in vitro was also highly effective in these fibroblasts, as illustrated in Figure 4D. 
TGF-β1 was a potent stimulator of the proliferation of cells treated with the control siRNA (Figure 5A). As not-
ed above, TGF-β1 was also a potent stimulator of fibroblast-to-myofibroblast differentiation, which was charac-
terized by enhanced expression of the myofibroblasts markers α-SMA and desmin (Figure 5, B and C). TGF-β1 
also stimulated extracellular matrix gene expression and activated Smad2 and Akt fibroblast signaling (Figure 
5, D and E). In all cases, these responses were at least partially Lama1 dependent, as treatment with Lama1 
siRNA significantly decreased TGF-β1–stimulated fibroblast proliferation, myofibroblast differentiation, matrix 
gene expression, and fibroblast signaling. When viewed in combination, these studies demonstrate that Lama1 
is a critical regulator of TGF-β1–stimulated fibroblast proliferation, myofibroblasts transformation, matrix gene 
expression, and the activation of its fibroblast signaling pathways.
Increased expression of  Lama1 in the lungs of  IPF patients. The studies noted above demonstrate that Lama1 
plays a critical role in the generation of  TGF-β1–induced fibroproliferative responses. This allows for the 
exciting hypothesis that exaggerated Lama1 expression is seen in human fibrotic disorders. To test this 
hypothesis, we evaluated the expression of  Lama1 in lung tissues from IPF patients and compared these 
findings to expression in lung tissues from normal control patients and patients with COPD. As shown in 
Figure 6, Lama1 expression was significantly increased in the lung tissues from IPF patients compared with 
normal and disease controls (Figure 6A). In keeping with our findings in TGF-β1 Tg mice, Lama1 IHC also 
demonstrated an increase in the number of  macrophage-like and interstitial fibroblast–like cells that contained 
Lama1 in lungs from IPF patients compared with the control cohort or COPD patients (Figure 6B). Double 
IHC with markers specific for fibroblasts (FSP-1) and macrophages (CD68) further confirmed that these cells 
were the major Lama1-positive cells in IPF patients (Figure 6C). Thus, in keeping with our murine findings, 
these studies demonstrate that enhanced Lama1 expression is present in lung tissues from patients with IPF.
Discussion
To further understand the pathogenesis of  a fibrotic disorders, we used what we believe to be a novel Tg 
approach and identified a genetic modifier of  TGF-β1–induced pulmonary fibrosis. Analysis of  a pan-
el of  10 inbred strains, each of  which had a similar level of  transgene-induced TGF-β1 overexpression, 
revealed that TGF-β1 was remarkably fibrogenic in some strains but minimally fibrogenic in others. By 
combining HBCGM and mRNA profiling, we identified Lama1 as a genetic modifier of  these different 
TGF-β1–induced pulmonary fibrotic responses. Moreover, we demonstrate that there are strain-specific 
differences in Lama1 mRNA expression in macrophages and fibroblasts and that Lama1 has unique roles 
in alternative and fibrogenic/reparative macrophage differentiation, fibroblast proliferation and signaling, 
and myofibroblast differentiation. Analysis of  lung tissue obtained from patients with IPF and COPD indi-
cates that these findings may translate to human pulmonary fibrotic diseases. This is the first study to our 
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Figure 4. Lama1 plays a critical role in alternative and fibrotic/reparative macrophage activation. Alveolar macrophages 
were isolated from the C57 mice and stimulated with recombinant IL-4 (rIL-4), rTGF-β, and rIFN-γ with (+) and without (–) in 
vitro siRNA silencing of Lama1 (Lama1 Si). (A) Expression of macrophage alternative activation markers was evaluated by 
qRT-PCR after 24-hour stimulation with rIL-4 (20 ng/ml). (B) Expression of alveolar macrophage fibrotic/reparative markers 
evaluated by qRT-PCR after 24-hour stimulation with rTGF-β1 (20 ng/ml). (C) Expression of macrophage classical activation 
markers evaluated by qRT-PCR after 24-hour stimulation with rIFN-γ (100 ng/ml). (D) Lama1 siRNA silencing efficacy on 
TGF-β stimulated Lama1 expression in alveolar macrophages evaluated by qRT-PCR. The values represent mean ± SEM of 
evaluations, with a minimum of 5 mice in each group. *P < 0.05, **P < 0.01, ***P < 0.001.
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knowledge to identify Lama1 as a genetic modifier of  pulmonary fibrosis. The discovery that Lama1 plays 
an important role in TGF-β1–induced pulmonary fibrosis has identified unique mechanisms that underlie 
the effects of  this genetic modifier. It also demonstrates that Lama1 could be an important new biomarker 
and/or therapeutic target for IPF and potentially other fibrotic disorders.
Strain-dependent susceptibility to developing tissue fibrotic responses have been demonstrated in ani-
mal models of  tissue fibrosis in the liver, kidney, intestine, skin, and lung (reviewed in ref. 39). Inbred 
strains are susceptible or resistant to the development of  pulmonary fibrosis after bleomycin challenge or 
adenoviral transfer of  active TGF-β1, and it has been shown that bleomycin induced pulmonary fibro-
sis strongly in C57 strains but weakly in BALB/c mice (39–42). However, the underlying genetic factors 
and mechanisms that contribute to these phenotype differences have not been fully defined. A prior study 
demonstrated that the state of  cellular activation and inducibility of  lysyl oxidase modulate the effects of  
TGF-β1 and strain-specific injury and repair responses to bleomycin (43). Our studies add to knowledge in 
this area by demonstrating that Lama1 is also an important modifier of  TGF-β1 tissue responses. Addition-
al investigation will be required to define the roles of  these genetic regulators, their relationships to each 
other, and the mechanisms they use to control tissue injury and fibroproliferative repair.
Our current genetic studies have also led to an understanding of  the dichotomous role of  TGF-β1 
in the pathogenesis of  fibrosis and emphysema. When we evaluated the degree of  alveolar destructive 
changes by measuring chord length of  all 10 strains of  mice, we also observed different levels of  emphy-
Figure 5. Lama1 plays a critical role in TGF-β–stimulated fibroblast proliferation, 
myofibroblast transformation, extracellular matrix protein expression, and acti-
vation of Akt and Smad2 signaling. Normal human lung fibroblasts (NHLFs) were 
treated with Lama1 siRNA or the scrambled control and stimulated for 24 hours with 
rTGF-β1 (20 ng/ml) or vehicle control. (A) Cellular proliferation was assessed using 
WST-1 evaluations. (B) Western blot evaluation of α–smooth muscle actin (α-SMA) and 
qRT-PCR evaluation of desmin expression. (C) IHC evaluation of α-SMA expression. 
Scale bars: 25 μm. (D) qRT-PCR evaluations of the expression of extracellular matrix 
proteins. (E) Western blot evaluation of Akt and Smad2 activation in fibroblasts treat-
ed with TGF-β1 or vehicle control with (+) and without (–) Lama1 siRNA silencing (Si). 
The values in A, B, and D represent mean ± SEM of triplicate evaluations in 3 separate 
experiments. *P < 0.05, **P < 0.01. Western blot and IHC evaluations in B, C, and E are 
representative of 3 separate experiments.
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sema depending on the strain (Supplemental Figure 9). Interestingly, we did not observe inverse relation-
ships between fibrosis and emphysema phenotypes in these strains of  mice. These studies led us to spec-
ulate that independent fibrogenic and emphysematous genetic modifiers determine the final outcome of  
the tissue phenotypes in the lungs of  TGF-β Tg mice. Thus, identification of  potential emphysematous 
genetic modifiers warrants further investigation.
In this study, we have demonstrated that haplotype analysis combined with expression profiling on a Tg 
model of  pulmonary fibrosis could be an effective tool to identify candidate gene(s) regulating pulmonary 
fibrosis. Since haplotype evaluation generates multiple candidate genes based on strain-dependent tissue 
phenotypes, it is important to identify reasonable candidate genes that can be validated with additional 
screening methods. Combining array evaluation on multiple strains of  mice with extreme phenotypes as 
we employed in this study, such as fibrosis-prone versus fibrosis-resistant strains of  mice, and haplotype 
analysis significantly increased the selectivity of  the candidate genes. However, our mRNA array evalu-
ation as a method of  candidate selection has intrinsic limitations that include the following: (i) the crite-
ria of  2-fold-up- and -downregulated genes in array analysis exclude a number of  genes with borderline 
changes that may have substantial expression alterations; (ii) the method excludes genes other than those 
Figure 6. Increased 
expression of Lama1 
in lungs from IPF 
patients. (A) Levels 
of mRNA encoding 
Lama1 were evaluated, 
using qRT-PCR, in lung 
tissues from normal 
controls, patients with 
COPD, and patients 
with IPF. (B) Repre-
sentative IHC staining 
of Lama1 in the lungs 
from controls and 
patients with IPF and 
COPD. Arrows indicate 
Lama1+ cells. Yellow 
arrows, fibroblasts-like 
cells; green arrows, 
macrophage-like cells. 
(C) Representative dou-
ble IHC staining using 
macrophage- (CD68) 
and fibroblast-specific 
markers with Lama1 
in lungs from IPF 
patients. *P < 0.05. 
Scale bars in B and C: 
50 μm.
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involved in transcriptional regulation. In this regard, 
it is interesting to note that more than half  of  the 
top 20 listed genes identified by haplotype analysis 
(listed in Supplemental Table 1) have been report-
ed to be associated with tissue fibrosis or extracel-
lular matrix remodeling in various organs, includ-
ing lung, liver, and heart. Among these, integrin α7 
(Itga7) was reported as a high-affinity receptor for 
laminin (laminin111) of  which Lama1 is a major 
component (44). This finding led us to the exciting 
hypothesis on the Itga7, as a signaling receptor for 
laminin, mediates enhanced Lama1 regulation of  
lung fibrosis. Thus, the top-listed genes generated by 
haplotype analysis warrant investigation in future 
studies with additional selection methods.
Laminins are heterotrimeric proteins that contain 
α, β, and γ subunits. As a component of  the extracel-
lular matrix, they are known to play an important role 
in maintaining tissue integrity and cellular differenti-
ation, migration, and adhesion (45). Currently about 
16 laminin heterotrimeric complexes are known to be 
expressed in a tissue-specific manner, and basement 
membranes are the major site of  laminin expression 
in the adult lung (45–47). In the adult lung, alveolar 
epithelial cells express mainly laminin α3 and α5, and 
lung fibroblasts express mostly α3 chains (45–47). 
Recent studies also reported aberrant expression of  
α3 subunits in pulmonary fibrosis (48). Lama1 is a 
major component of  the laminin 111 heterotrimeric 
complex, which is known to be expressed in the 
basement membranes of  various tissues (49). How-
ever, Lama1 expression in the lung is mostly restrict-
ed to the period of  lung morphogenesis and is not 
expressed in an obvious manner in adult lungs (47). It 
is believed to play a critical role in lung development, 
because constitutive null mutations of  Lama1 are embryonically lethal (50). However, the expression and 
contributions of  Lama1 to the pathogenesis of  pulmonary fibrosis have not been investigated. Our studies add 
to understanding of  the biology of  Lama1. They are the first to our knowledge to demonstrate that Lama1 is 
a modifier of  TGF-β1 responses and plays a critical role in TGF-β1–induced pulmonary fibrosis. They also 
demonstrate that Lama1 is significantly induced in the lungs of  TGF-β1 Tg mice with pulmonary fibrosis and 
lungs from patients with IPF. Interestingly, in both settings, macrophages were the most prominent site of  
Lama1 expression, and Lama1 was shown to be uniquely able to regulate alternative and fibrotic macrophage 
activation. Both are known to be critical events in the pathogenesis of  fibrotic tissue responses (36, 51–53). 
Lama1 was also induced by TGF-β1 in fibroblasts, where it played a critical role in fibroblast proliferation and 
signaling and myofibroblast differentiation. This further clarifies the mechanisms that Lama1 uses in fibrotic 
tissue responses. Interestingly, the siRNA silencing of  Lama1 and a functional missense mutation (Y265C) 
that blocks the optimal interaction between Lama1 and other molecules (38) caused similar changes in macro-
phage activation. These data further support the contention that Lama1 plays a critical role in alternative and 
fibrotic macrophage activation and ultimately fibrotic tissue responses in the lung.
After tissue injury, monocytes and macrophages undergo marked phenotypic and functional changes to 
play critical roles in the initiation, maintenance, and resolution phases of  tissue repair (36). There is also accu-
mulating evidence that different monocyte and macrophage populations play distinct roles in tissue repair, 
fibrosis, and regeneration and that disturbances in macrophage function can lead to aberrant states that can 
contribute to a state of  persistent injury that can lead to pathological fibrosis (36). A variety of  pathways 
Table 2. Demographic and clinical characteristics of control, COPD and IPF 
patients used in this study
COPD IPF Control
Demographics
n 7 17 19
Age 62.4 ± 7.9 65.54 ± 5.5 43.05 ± 14
Smoking
No 1 9 14
Yes 5 8 4
Sex
Female 1 3 3
Male 6 14 16
Race
European descent 7 27 N/A
Pulmonary function test
FEV1 (%) 25 ± 13.77 52.94 ± 11.5
FVC (%) 49.2 ± 21.4 47.47 ± 12.5
FEV1/FVC 40.2 ± 10 87.8 ± 6
TLC (%) 99.8 ± 39 50.53 ± 12.4
IC (%) 49.5 ± 19.1 41 ± 10.5 N/A
FCR (%) 145.8 ± 74 59.2 ± 18
RV (%) 165 ± 107 54 ± 27
DLCO (%) 32 ± 14 29 ± 7.5
Cardiac catheterization
Mean PAP (mmHg) 27.8 ± 8.55 25.4 ± 8.3
PCWP (mmHg) 10.34 ± 2.87 9.76 ± 3.01
Mean RA (cm) 7.42 ± 3.59 5.5 ± 2.52 N/A
CO (l/m) 6.89 ± 1.44 5.97 ± 0.80
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity. TLC, total lung 
capacity; IC, inspiratory capacity; FCR, functional residual capacity; RV, residual volume; 
DLCO, diffusing capacity for carbon monoxide; PAP, pulmonary arterial pressure; PCWP, 
pulmonary capillary wedge pressure. RA, right atrium.
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of macrophage differentiation have been described, including classic, alternative, and reparative phenotypes 
(reviewed in ref. 36). Our studies add to our understanding of  macrophage biology by demonstrating that 
TGF-β1 is a potent stimulator of  macrophage Lama1 and that Lama1 does not contribute to classic but is 
critical for the alternative and fibrotic/reparative macrophage activation observed at sites of  injury and repair. 
The mechanism(s) by which Lama1 mediates these responses will require additional investigation.
In summary, our studies have established a methodology that utilizes Tg, in silico haplotype, and 
microarray approaches to define genetic modifiers of  mediator function and used this approach to demon-
strate that Lama1 is a genetic modifier of  TGF-β1–induced pulmonary fibrosis. These studies also high-
lighted important new mechanisms by which the effects of  Lama1 are mediated, by demonstrating that 
Lama1 plays a critical role in alternative and fibrotic macrophage activation, fibroblast proliferation and 
signaling, and myofibroblast transformation. Importantly, they also demonstrated that Lama1 is expressed 
in an exaggerated fashion in the lungs and lung macrophages of  patients with IPF. When viewed in com-
bination, these studies suggest that Lama1 is a genetic modifier of  TGF-β1 responses and could be a bio-
marker and therapeutic target in pulmonary fibrosis. Additional studies of  TGF-β1 genetic modifiers and 
the biology of  Lama1 in fibrosis are warranted.
Methods
Mice. WT C57, BALB/cJ, C3H/HeJ, CBA/J, 129Si/J, FVB/J, NZW/J, DBA/J, AKR/J, and A/J mice 
were purchased from the Jackson Laboratory and were housed at Brown University animal facilities. 
TGF-β1 Tg mice were generated, characterized, and maintained in our laboratory as previously described 
(34). TGF-β1 Tg mice on 10 different background strains were generated by continuously backcrossing C57 
TGF-β1 Tg mice with other WT strains of  mice for more than 10 generations. For transgene induction in 
TGF-β1 Tg mice, 6- to 8-week-old transgene+ and transgene– littermate controls were randomized to nor-
mal water or water containing 0.5 mg/ml doxycycline as described previously (34). Chemically induced, 
viable Lama1 mutant mice on a C57 background (C57BL/6J-Lama1nmf223) (38) were purchased from the 
Jackson Laboratory and used for macrophage preparation.
Histologic analysis. The lungs were removed en bloc, inflated at 25-cm pressure with neutral buffered 
10% formalin, fixed in 10% formalin, embedded in paraffin, sectioned, and stained. H&E and Mallory 
trichrome staining were performed in the Molecular Pathology Core at Brown University.
Sircol collagen assay. Animals were anesthetized, a median sternotomy was performed, and right heart 
perfusion was completed with calcium- and magnesium-free PBS. The heart and lungs were then removed. 
Right lungs were frozen in liquid nitrogen and stored at −80°C until they were used. Collagen content was 
determined by quantifying total soluble collagen using the Sircol collagen assay kit (Biocolor, Accurate 
Chemical & Scientific Corp.) according to the instructions of  the manufacturer.
HBCGM analysis. Genetic factors were identified using the HBCGM methods previously described (35, 
54). In brief, HBCGM utilizes biallelic SNPs that are polymorphic among the analyzed strains. These 
SNPs usually display a limited degree of  variation locally among the strains. Haplotype blocks were then 
constructed using methods described previously (54). The pattern of  genetic variation within each block 
was correlated with the distribution of  trait values among the strains analyzed by using ANOVA-based 
statistical modeling. P values from the ANOVA model and the corresponding genetic effect size were calcu-
lated for each block as previously described (55). The blocks were then ranked by their P values, and those 
below an input threshold were used as candidate predictions.
mRNA profiling with array analysis. The mRNA expression profiling on the fibrosis-prone strains (C57, 
AKR/J, A/J strains) versus fibrosis-resistant strains of  mice (C3H/HeJ, 129Si/J, BALB/cJ) was done 
using an Affymetrix Mouse 1.0 ST array according to the manufacturer’s instructions. Three TGF-β1 Tg 
mice on each strain together with WT controls were subjected to Affymetrix evaluation, and the data have 
been filed in the NCBI’s Gene Expression Omnibus database (GEO GSE119662). Normalization was 
carried out using the robust multiarray average (RMA) method (56) to generate one expression measure for 
each probe set on each array. For each strain, the fold change in the expression level of  each gene between 
Tg and control mice was evaluated. The average fold change for the 3 fibrosis-prone strains and that for the 
3 fibrosis-resistant strains was evaluated. 127 genes that met the specified criteria (average fold change >2 in 
fibrosis-prone strains and <2 in fibrosis-resistant strains) were identified and intersected with the candidate 
gene list identified by HBCGM analysis. In this analysis, the statistical significance of  the expression differ-
ence between Tg mice and controls was not assessed. We acknowledge that this practice could increase the 
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rate of  false-positive findings, but we argue that the false-negative rate will be greatly increased by enforcing 
a stringent statistical significance threshold, which could mistakenly filter out true genetic factors, which 
would not be recovered in the subsequent analysis. On the other hand, we controlled the false-positive 
rate by intersecting with the orthogonal information (57), which was the HBCGM analysis result in this 
case. We further rigorously validated the biological function of  the Lama1 gene experimentally. Therefore, 
although we applied loose candidate selection criteria in one step of  the whole analysis, we applied an 
additional candidate selection process and completed a functional test to ensure the validity of  our findings.
Real-time quantitative RT-PCR. mRNA levels were assessed using real-time quantitative RT-PCR (qRT-
PCR) assays. In these assays, total cellular RNA from lungs or other mouse tissues were obtained using 
TRIzol reagent (Gibco) and RNeasy Mini Kit (QIAGEN) according to the manufacturer’s instructions.
IHC evaluation. To localize the expression of  Lama1, single- or double-label IHC was undertaken with 
a modification of  procedures described previously by our laboratory (58). First, slides were deparaffinized 
in xylene, rehydrated in an ethanol gradient, and washed in PBS. To unmask antigens, slides were placed 
for 20 minutes at high temperature under high pressure in citrate buffer (10 mM sodium citrate, 0.05% 
Tween 20, pH 6). Tissue sections were then blocked with a non-serum protein-blocking reagent (DakoCy-
tomation Inc.) for 1 hour at room temperature (RT) and incubated with primary antibodies (anti-Lama1, 
1:50 dilution, AF-3559, R&D Systems; and anti-CD68, 1:50 dilution, 12829S, Cell Signaling Technology) 
for 60 minutes at RT in a humid chamber. Substitution of  the primary antibody with PBS served as a 
negative control. The slides were then washed in PBST (0.01 % Tween 20) and incubated with secondary 
antibodies conjugated with horseradish peroxidase (Cell Signaling Technology). Reaction products were 
developed using diaminobenzidine (DAB) containing 0.3% hydrogen peroxide up to 5 minutes. Cell nuclei 
were stained with VECTASHIELD Antifade Mounting Medium with DAPI (50 μl, H-1200, VECTOR 
Laboratories). Fluorescence was detected by immunofluorescence microscopy.
Immunoblot assay. 50 μg BAL fluids and/or lung lysates were subjected to immunoblot analysis using 
α-SMA, phosphorylated ERK (pERK), total ERK (TERK), pAkt, and total AKT (TAKT). These samples 
were gel fractionated, transferred to membranes, and evaluated as described previously by our laboratory (34).
Establish primary lung fibroblasts from C57 and BALB/c mice. According to the reported protocol (59), ex 
vivo lung was first chopped into small pieces, then incubated in Liberase Blendzyme solution (grade III, 
0.14 Wünsch U/ml, Roche) for 30 minutes under a tube rotator in a 37°C incubator. The suspension was 
filtered through a 70-μm nylon mesh and was centrifuged at 400 g for 3 minutes. The cell pellet was resus-
pended into DMEM/F12 media with 15% FBS, 1× antibiotic/antimycotic and plated in a 10-cm2 tissue 
culture dish at 37°C/5% CO2. Fourteen days after the beginning of  the cell isolation, it was changed into 
EMEM with 15% FBS and 1× penicillin/streptomycin.
Isolation of  alveolar macrophages from the lungs of  mice. Mice were sacrificed using intraperitoneal ketamine/
xylazine injection, and the trachea was cannulated and perfused with two 0.9-ml aliquots of  cold saline. The 
cellular contents were resuspended into RPMI1640 media with 10% FBS and 1× penicillin/streptomycin and 
were plated in 10-cm2 tissue flasks at 37°C/5% CO2. After 1 day, floating cells were discarded and media was 
changed. We identified macrophage population to be greater than 95% through the flow cytometry.
In vivo Lama1 siRNA silencing. In vivo siRNA silencing targeting Lama1 in the lung was done according 
to procedures previously described by our laboratory (60, 61). In brief, scrambled siRNA and Lama1-tar-
geted siRNAs were selected and synthesized by Bioneer Inc. and delivered to mice intranasally at a dose of  
3 nmol/mouse/d, once a day for 14 days. Six-to 8-week-old TGF-β1 Tg mice and control littermates were 
randomized to receive either Lama1 siRNA or scrambled control siRNA. Starting on the second day of  
treatment, both WT and TGF-β1 Tg mice were given water containing 0.5 mg/ml doxycycline for trans-
gene induction, as described previously (34).
In vitro Lama1 siRNA silencing. Specific siRNA silencing was done according to previously described 
procedures (61). In brief, NHLFs (Lonza, CC-2512) (0.5 × 106 cells/250 μl) were seeded in each well of  a 
48-well plate. According to the manufacturer’s protocol for siRNA transfection, 12.5 μl OptiMEM contain-
ing 5 μM siRNA was added to 12.5 μl OptiMEM containing 2 μl Lipofectamine 2000 (Invitrogen) after a 
5-minute incubation at RT. After gentle mixing, the siRNA-Lipofectamine mixture was incubated at RT for 
10 minutes and added to the cells.
Profiling of  IPF, COPD, and control lung tissues. Fresh human lung tissue was obtained from subjects with end-
stage lung disease undergoing transplant or donor lungs that were not implanted at the time of transplant. The 
demographics and clinical characteristics of the groups are shown in Table 2. All protocols were approved by the 
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Partners HealthCare Institutional Review Board. For each subject, small pieces (<5 mm) of whole lung tissue 
were treated with RNAlater (QIAGEN) and snap frozen in liquid nitrogen prior to storage at –80°C.
Information on the primers and antibodies used in this study. The primer sequences used for qRT-PCR and 
antibodies used for immunoblot or IHC evaluation are shown in Supplemental Tables 3 and 4, respectively.
Statistics. Normally distributed data are expressed as mean ± SEM and were assessed for significance 
by Student’s t test or ANOVA, as appropriate. Data that are not normally distributed were assessed for 
significance using a Kruskal-Wallis test, followed by a Dunn’s post hoc test for multiple comparisons or 
Mann-Whitney U test for a 2-group comparison.
Study approval. Mice were housed and all experimental procedures performed in an Association for 
Assessment and Accreditation of  Laboratory Animal Care–accredited laboratory animal facility at Brown 
University. This study was approved by the Brown Institutional Animal Care and Use Committee and 
adhered to the NIH’s Guide for the Care and Use of  Laboratory Animals (National Academies Press, 2011). 
All protocols for obtaining and use of  human lung tissues were approved by the Partners HealthCare Insti-
tutional Review Board, and written informed consent was obtained from research subjects or authorized 
health care proxies before or at the time of  tissue procurement.
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